Introducing 

Prezi AI.

Your new presentation assistant.

Refine, enhance, and tailor your content, source relevant images, and edit visuals quicker than ever before.

Loading content…
Transcript

BIOPURE - CASE STUDY

BY: JULIAN, ADRIANA, NICHOLAS, DANIEL, TIANNA & FERNANDO

Before Selecting Alternatives....

Baxter International &

Northfield Laboratories

1) Launch Oxyglobin first, then launch Hemopure whenever it gets approved (IPO 1 YR after Oxyglobin launch)

2) Wait to launch Hemopure and shelf Oxyglobin for the time being (IPO 1 YR after launching both).

3) Launch Oxyglobin first, then when Hemopure gets approved cut Oxyglobin and only sell 1 product (IPO when Oxyglobin is strong).

THANK YOU!

Positioning Statement

Going Forward...

Product Strategy

Conclusion:

Option #1

Launch Oxyglobin & then 50/50 split with Hemopure

Key Aspects:

-Break-Even

-2 Markets

-Beneficial even without FDA

-Innovator in product category

Critical Analysis

Decision Making Process

Value Creation

Changing Market Outlook

Option #1

Assumptions & FDA

Option #2

Option #3

Alternatives

INTRODUCTION

  • What is Biopure?

  • Oxyglobin vs Hemopure
  • Carl Rausch, CEO
  • Ted Jacobs, VP of Human Clinical Trails
  • Andy Wright, VP of Veterinary Products

BIOPURE

CORPORATION

add logo here

Learn more about creating dynamic, engaging presentations with Prezi